Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex Hypertension Clinic. Read his story.

The Saudi Food and Drug Authority (SFDA) has approved the registration of Winrevair (sotatercept) for the treatment of adult patients with World Health Organization (WHO) Functional Class II to III ...

In PAH, high blood levels of a protein called CTRP7 may predict a poor patient response to the approved therapy Uptravi, a ...

New columnist Jolie Lizana shares her harrowing journey to a pulmonary hypertension diagnosis and finding purpose in advocacy ...

The pulmonary arterial hypertension market is expected to reach USD 2,080.7 million by 2025 and is expected to steadily grow at a CAGR of 2.3% to reach USD 2,612.0 million by 2035.

Sotatercept, an activin-signalling inhibitor, is a promising add-on treatment for patients with advanced pulmonary arterial hypertension and a high risk of death, according to data from the ZENITH ...

Blood pressure drops Significant drops in blood pressure after exercise are a risk factor for hypertension and certain types of heart disease.

Chronic obstructive pulmonary disease (COPD) is a disease of the respiratory tract that is characterized narrowing of the small airways and destruction of lung tissue.

The UK medicines regulator has awarded Alnylam's RNAi-based therapy zilebesiran for hypertension an 'innovation passport', a designation designed to speed up NHS access to promising new medicines ...

Boehringer drug scores in another pulmonary fibrosis trial Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.